Skip to content
Peptide Insider

Comparison

CJC-1295 vs Ipamorelin

CJC-1295 and ipamorelin are routinely discussed as a pair, on the reasoning that stimulating the growth hormone axis at two different points should produce more effect than stimulating it at one. The mechanistic logic is real. What is missing is any published human trial testing the combination — or, for either compound individually, any trial measuring a clinical outcome successfully.

Written by Peptide Insider Editorial TeamPublished Last reviewed

Side by side

Every row is traceable to the linked compound profile. Note that this table has no “best for” row: framing investigational compounds that way reads as a treatment recommendation, so we compare primary areas of research instead.

AttributeCJC-1295Not FDA approvedIpamorelinNot FDA approved
Receptor targetGHRH receptor (pituitary somatotrophs)Ghrelin receptor GHS-R1a
Primary area of researchGrowth hormone axis pharmacology; intended for growth hormone deficiencyPostoperative ileus; growth hormone axis pharmacology
Research stageClinical ResearchClinical Research
Overall evidence levelEARLY CLINICALEARLY CLINICAL
Human trials conductedRandomised placebo-controlled Phase 1 in healthy adultsRandomised placebo-controlled Phase 2 in 117 bowel-resection patients
Endpoint testedGH and IGF-1 concentrations (surrogate)Time to tolerating a solid meal (clinical)
ResultGH raised 2–10× for ≥6 days; IGF-1 raised 1.5–3× for 9–11 daysMissed primary endpoint (25.3 h vs 32.6 h, p = 0.15)
Reported half-lifeApproximately 5.8–8.1 days (with DAC)Short; dosed twice daily in the trial
FDA approvalNoNo
FDA 503A compounding statusNomination withdrawnCategory 2 — identified significant safety risks
Principal open questionDoes sustained GH and IGF-1 elevation produce any clinical benefit, and at what long-term cost?Would an adequately powered trial have detected the effect the Phase 2 study suggested but could not confirm?

Different doors to the same room

Growth hormone release from the pituitary is controlled by two opposing upstream signals plus a stimulatory input from ghrelin. CJC-1295 acts on the GHRH receptor; ipamorelin acts on the ghrelin receptor. Both increase growth hormone output by different routes, which is the basis for the idea that combining them should be additive.

That idea has not been tested in a published human trial. It remains a reasonable hypothesis about pharmacology, and reasonable hypotheses about pharmacology fail in trials routinely.

The important asymmetry

These two compounds sit at the same evidence level for a reason that is easy to miss: they got there by opposite routes.

CJC-1295 has a clean positive result on a surrogate endpoint. Its Phase 1 programme established, with placebo control and dose ranging, that the compound does what it was designed to do to hormone concentrations. Nobody then asked whether that helps.

Ipamorelin has a clean negative result on a clinical endpoint. Somebody did ask whether it helps, in 117 randomised patients, and the answer did not reach significance.

For a reader trying to decide which compound is better supported, the second is the more informative record — not because the result was favourable, but because the question was real. See growth hormone secretagogues: what the human evidence shows for the class-level picture, including tesamorelin, the only member with an approval.

The regulatory difference is not cosmetic

CJC-1295 appears on FDA's 503A page among substances whose nominations were withdrawn. Ipamorelin acetate sits in Category 2 — nominated, evaluated, and flagged for identified significant safety risks.

A withdrawn nomination is an administrative event. A Category 2 listing is a substantive determination by the agency. Anyone weighing these compounds against each other should weigh that difference too.

Frequently asked questions

Is the CJC-1295 and ipamorelin combination studied?
Not in any published human trial we have identified. The rationale for combining them is mechanistic — two different upstream receptors — but no controlled study has tested the combination in people.
Which has better evidence?
Neither is well supported for any clinical use. CJC-1295 has a positive Phase 1 result on hormone levels; ipamorelin has a negative Phase 2 result on a clinical endpoint. The second tested a more meaningful question.
Is either approved by the FDA?
No. Ipamorelin acetate is additionally listed by FDA in Category 2 of its interim 503A bulks policy, meaning the agency has identified significant safety risks.

Other comparisons

Comparison

BPC-157 vs TB-500

Two research compounds discussed interchangeably for tissue repair. Their mechanisms, their evidence bases and their regulatory positions are not the same.

Comparison

Semaglutide vs Tirzepatide vs Retatrutide

One, two and three receptors. Two approved drugs and one investigational compound. What the trials measured, what the labels say, and where the differences actually lie.

Comparison

Tesamorelin vs CJC-1295

Two GHRH analogs with the same upstream mechanism and completely different evidence. What separates an approved medicine from a discontinued research compound.

References

Peptide Insider cites primary sources wherever they exist — regulatory documents, trial registrations and peer-reviewed literature — in preference to secondary summaries.

  1. 1.
    Teichman SL, Neale A, Lawrence B, et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 2006;91(3):799–805.
    Peer-reviewedDOI: 10.1210/jc.2005-1536PMID: 16352683
  2. 2.
    Beck DE, Sweeney WB, McCarter MD, et al.. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 2014;29(12):1527–1534.
    Peer-reviewedDOI: 10.1007/s00384-014-2030-8
  3. 3.
    U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA, 2026;Page last updated 22 April 2026.
    Regulatory